Trajan Group Holdings Ltd · ASX:TRJ
Trajan — H1 FY26 Earnings Presentation
18 slides from Trajan's earnings presentation, Feb 26, 2026
Slide 1: H1 FY26 Results
www.trajanscimed.com H1 FY26 Results July 01, 2025 – December 31, 2025 Stephen Tomisich, CEO and Alister Hodges, CFO – Webcast 26 February, 2026
Slide 2: Trajan Scientific and Medical
Trajan Scientific and Medical Operating Segment Strengths We are a global developer and manufacturer of analytical and life Components & Consumables science products and devices, founded to have a positive impact Recurrent Revenue; multiple on human wellbeing. channels to market; regional agility. •
Slide 3: FY26 H1 – A tale of two Quarters
FY26 H1 – A tale of two Quarters Q1 challenges with progressive recovery in Q2 Main obstacles in H1 Recovery indicators for H2 • Purchasing caution in Capital Equipment, coinciding • Record group revenue in Q2 with slowdown in Pharmaceutical and Food; and US • Growth in the Capital Equipment order b
Slide 4: Margin and Guidance
Margin and Guidance In addition to macro economic factors observed in H1 FY2026, margin enhancement delays also resulted from: • Additional benefits from Project Neptune were slower than expected. • Production site inefficiencies and inter-site costs whilst establishing “in region for region” capabi
Slide 5: Headwinds and Tailwinds in FY26
Headwinds and Tailwinds in FY26 Headwinds • Macroeconomic environment • Tariff volatility drives uncertainty • Availability of Government funding • Geopolitical unrest • Volatile currency exchange rates Tailwinds • Sector reporting a return to growth • Pharma recovering • Capital Equipment Food orde
Slide 6: The Road Ahead
The Road Ahead • H2 baseline nEBITDA $8.6M (based on Q2 run rate). • Resource reductions, Project Neptune driven, $0.8M. • Pricing actions, $1.3M. • Supply Chain and growth initiative, $0.3M. * Risk; further revaluation of offshore assets with escalation of AUD 6
Slide 7: FY26 H1 Financial Summary
e ee s sah = |. ¥ " Enriching Personal Health Through Scientific Tools and Soluti' tT + [ = - — : ? si @TRA , JAN | Science that benefits people
Slide 8: H1 FY2026 Financial Summary
H1 FY2026 Financial Summary Group Revenue UP Group nEBITDA* DOWN $84.1M 3.8% $5.0M 36.2% PCP: $81.0M PCP: $7.9M 10.7 11.0 8.9 8.3 7.9 7.6 5.0 4.0 nEBITDA - Group Cash Balance Proforma Gross Margin Operating NPATA** $12.7M up 6.7% 37.4% down 2.3pts $0.8M down 20% 30 June 2025 $11.9M PCP 39.7% PCP $1.
Slide 9: Operating Segments
Operating Segments
Slide 10: Components & Consumables
Components & Consumables • Revenue growth across the Component & Consumables product range, in a difficult half, Net Revenue Gross Margin nEBITDA* speaks to the resilience of this segment. $51.9M up 6.1% 37.5% down 3.7pts $15.2M down 6.3% • “ In region for region” capability impacts this PCP $48.9M
Slide 11: Capital Equipment
Capital Equipment • Order book balance of $10.8M at the end of H1, creates momentum for H2 FY26. • Pharma market customer activity, especially in EU, has picked up. Net Revenue Gross Margin nEBITDA* • New clinical systems expected to contribute to H2. $29.1M down 2.7% 35.3% down 0.9pts $4.8M down 14
Slide 12: Disruptive Technologies
Disruptive Technologies • Excellent revenue growth (+40%) in this segment is attributable to the Microsampling portfolio, which now operates at a profit. Net Revenue Gross Margin nEBITDA* • Microsampling device sales are moving from $3.1M up 40.2% 53.6% up 0.6pts ($0.3M) up 69.4% isolated proof-of-c
Slide 13: Cashflow Summary
Cashflow Summary Dec 2025 Dec 2024 • Movement in net working capital due to increase in inventories ($M) ($M) $0.9M, decrease in receivables $2.8M, increase in other Normalised EBITDA* 5.0 7.9 assets $0.9M, decrease in payables $4.4M and increase in Income tax payments 0.1 (0.2) deferred revenue $0.
Slide 14: Fundamentals
Fundamentals TRAJAN | =
Slide 15: Strong Business Foundation
Strong Business Foundation • Robust business model with 15-year history as Trajan Scientific and Medical. • Sticky global customer base with high barriers to market entry. • Strong partner respect – OEM and distribution partners value our ability to mitigate tariff interference and deliver quality p
Slide 16: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 26th February 2026. The information in the presentation is provided for information purposes only, is in summary form and does n
Slide 17: Q&A
Q&A Segment title www.trajanscimed.com17
Slide 18: Thank you
Thank you Segment title www.trajanscimed.com18
Trajan Group Holdings — H1 FY26 Earnings Presentation on 6ix